Olmesartan Medoxomil/Amlodipine/Hct Accord (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan blocks the angiotensin II type‑1 (AT1) receptor, preventing angiotensin‑II‑induced vasoconstriction and aldosterone release. This action reduces systemic vascular resistance and lowers blood pressure, complementing the calcium‑channel blocking effect of amlodipine and the diuretic effect of hydrochlorothiazide.

The specific dose of Olmesartan Medoxomil/Amlodipine/HCT Accord is determined by the prescribing clinician based on the patient’s blood‑pressure readings, comorbidities, and response to therapy. Dosage adjustments are made under medical supervision and should follow the prescriber’s instructions.

Olmesartan, an ARB, is contraindicated in pregnancy, particularly in the second and third trimesters, due to risk of fetal toxicity. Breastfeeding is not recommended because the drug may pass into milk. Women who are pregnant, planning pregnancy, or nursing should discuss alternative treatments with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team then provides pricing, availability, shipping details and necessary import documentation.

Compared with monotherapy, the Olmesartan/Amlodipine/HCT combination offers synergistic blood‑pressure reduction by targeting three complementary pathways: the renin‑angiotensin system, calcium‑mediated vascular tone, and fluid volume. This can improve efficacy and simplify regimens versus taking separate tablets, while maintaining a safety profile consistent with each individual component.

Store the tablets at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the container tightly closed and out of reach of children. No refrigeration is required for this oral fixed‑dose combination.

The medication is taken orally, usually once daily, with or without food, as directed by a healthcare professional. Swallow the tablet whole with a glass of water; do not split, crush, or chew unless specifically instructed by a prescriber.

Serious risks include angio‑edema, severe hypotension, acute kidney injury, electrolyte disturbances such as hyper‑ or hyponatraemia, and rare severe skin reactions. Patients should seek immediate medical attention if they experience swelling of the face or throat, sudden dizziness, or unexplained rash.

The combination should be avoided in patients with known hypersensitivity to any component, those in the second or third trimester of pregnancy, and individuals with severe renal impairment or uncontrolled electrolyte imbalances unless closely monitored by a physician.